Jos Jonkers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6828828/publications.pdf

Version: 2024-02-01

268 papers	30,020 citations	5248 83 h-index	5364 164 g-index
284 all docs	284 docs citations	284 times ranked	41345 citing authors

#	Article	IF	Citations
1	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 534, 47-54.	13.7	1,760
2	Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 2014, 4, 998-1013.	7.7	1,341
3	IL-17-producing Î³Î´ T cells and neutrophils conspire to promote breast cancer metastasis. Nature, 2015, 522, 345-348.	13.7	1,303
4	Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genetics, 2001, 29, 418-425.	9.4	933
5	High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17079-17084.	3.3	854
6	53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Structural and Molecular Biology, 2010, 17, 688-695.	3.6	846
7	Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature, 2016, 535, 382-387.	13.7	685
8	Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways. Cell, 2014, 159, 499-513.	13.5	659
9	Longâ€term expanding human airway organoids for disease modeling. EMBO Journal, 2019, 38, .	3.5	619
10	Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 2017, 17, 254-268.	12.8	527
11	Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9209-9214.	3.3	526
12	Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell, 2006, 10, 437-449.	7.7	522
13	The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nature Reviews Cancer, 2012, 12, 587-598.	12.8	509
14	Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during Development. Molecular and Cellular Biology, 2006, 26, 5015-5022.	1.1	496
15	REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature, 2015, 521, 541-544.	13.7	487
16	The shieldin complex mediates 53BP1-dependent DNA repair. Nature, 2018, 560, 117-121.	13.7	445
17	PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discovery, 2019, 9, 722-737.	7.7	433
18	Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12111-12116.	3.3	428

#	Article	IF	Citations
19	Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors. Cancer Discovery, 2013, 3, 68-81.	7.7	428
20	Axin and Frat1 interact with Dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO Journal, 1999, 18, 4233-4240.	3.5	360
21	Genetically engineered mouse models in oncology research and cancer medicine. EMBO Molecular Medicine, 2017, 9, 137-153.	3.3	356
22	Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature, 2019, 572, 538-542.	13.7	312
23	A highly efficient ligandâ€regulated Cre recombinase mouse line shows that LoxP recombination is position dependent. EMBO Reports, 2001, 2, 292-297.	2.0	311
24	Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin. Clinical Cancer Research, 2008, 14, 3916-3925.	3.2	299
25	Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors. Molecular and Cellular Biology, 2004, 24, 6104-6115.	1.1	286
26	Conditional mouse models of sporadic cancer. Nature Reviews Cancer, 2002, 2, 251-265.	12.8	283
27	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Annals of Oncology, 2018, 29, 1203-1210.	0.6	280
28	Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12117-12122.	3.3	279
29	EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nature Cell Biology, 2017, 19, 1371-1378.	4.6	257
30	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. Journal of Experimental Medicine, 2013, 210, 1529-1544.	4.2	239
31	Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. Cancer Cell, 2018, 33, 1078-1093.e12.	7.7	238
32	Human and mouse oligonucleotide-based array CGH. Nucleic Acids Research, 2005, 33, e192-e192.	6.5	231
33	Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping. Nature Biotechnology, 2014, 32, 1019-1025.	9.4	231
34	BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance. Cancer Cell, 2011, 20, 797-809.	7.7	228
35	Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene, 2006, 25, 5885-5897.	2.6	221
36	The BRCA1-Î”11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Research, 2016, 76, 2778-2790.	0.4	208

#	Article	IF	Citations
37	CIP2A Is Associated with Human Breast Cancer Aggressivity. Clinical Cancer Research, 2009, 15, 5092-5100.	3.2	205
38	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nature Reviews Clinical Oncology, 2021, 18, 773-791.	12.5	198
39	BRD7 is a candidate tumour suppressor gene required for p53 function. Nature Cell Biology, 2010, 12, 380-389.	4.6	194
40	How do real tumors become resistant to cisplatin?. Cell Cycle, 2008, 7, 1353-1359.	1.3	185
41	MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nature Genetics, 2007, 39, 759-769.	9.4	184
42	An Î±â€Ÿâ€catenin (<scp>CTNNA1</scp>) mutation in hereditary diffuse gastric cancer. Journal of Pathology, 2013, 229, 621-629.	2.1	184
43	CopywriteR: DNA copy number detection from off-target sequence data. Genome Biology, 2015, 16, 49.	3.8	183
44	Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiological Genomics, 2007, 31, 32-41.	1.0	169
45	A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation. EMBO Molecular Medicine, 2018, 10, .	3.3	169
46	Ductal carcinoma in situ: to treat or not to treat, that is the question. British Journal of Cancer, 2019, 121, 285-292.	2.9	168
47	NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO Journal, 2008, 27, 2603-2615.	3.5	167
48	Large-Scale Mutagenesis in p19ARF- and p53-Deficient Mice Identifies Cancer Genes and Their Collaborative Networks. Cell, 2008, 133, 727-741.	13.5	167
49	Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. Journal of the National Cancer Institute, 2016, 108, djw148.	3.0	157
50	Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Research, 2002, 62, 1862-7.	0.4	155
51	A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nature Protocols, 2009, 4, 789-798.	5.5	150
52	Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment. Cancer and Metastasis Reviews, 2018, 37, 577-597.	2.7	150
53	Easy quantification of template-directed CRISPR/Cas9 editing. Nucleic Acids Research, 2018, 46, e58-e58.	6.5	147
54	Functional Ex Vivo Assay to Select Homologous Recombinationâ€“Deficient Breast Tumors for PARP Inhibitor Treatment. Clinical Cancer Research, 2014, 20, 4816-4826.	3.2	144

#	Article	IF	Citations
55	High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer. Cancer Research, 2009, 69, 3625-3633.	0.4	142
56	Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Molecular Cell, 2021, 81, 3128-3144.e7.	4.5	142
57	BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping. Nature Structural and Molecular Biology, 2010, 17, 1461-1469.	3.6	140
58	Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?. Clinical Cancer Research, 2014, 20, 540-547.	3.2	137
59	Mutagenic Insertion and Chromosome Engineering Resource (MICER). Nature Genetics, 2004, 36, 867-871.	9.4	134
60	Developmental stageâ€specific contribution of <scp>LGR5</scp>⁺ cells to basal and luminal epithelial lineages in the postnatal mammary gland. Journal of Pathology, 2012, 228, 300-309.	2.1	134
61	The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. Cancer Cell, 2018, 34, 197-210.e5.	7.7	130
62	Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nature Cell Biology, 2019, 21, 511-521.	4.6	121
63	Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas. EMBO Journal, 1997, 16, 441-450.	3.5	119
64	Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. DMM Disease Models and Mechanisms, 2011, 4, 347-358.	1.2	119
65	HELB Is a Feedback Inhibitor of DNA End Resection. Molecular Cell, 2016, 61, 405-418.	4.5	119
66	Bmi1 Regulates Stem Cells and Proliferation and Differentiation of Committed Cells in Mammary Epithelium. Current Biology, 2008, 18, 1094-1099.	1.8	118
67	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	9.4	118
68	Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiotherapy and Oncology, 2015, 116, 358-365.	0.3	115
69	Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochimica Et Biophysica Acta: Reviews on Cancer, 1996, 1287, 29-57.	3.3	114
70	Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes and Development, 2016, 30, 1470-1480.	2.7	113
71	Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. Journal of Clinical Investigation, 2011, 121, 3176-3188.	3.9	113
72	BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. Nature Methods, 2018, 15, 134-140.	9.0	110

#	Article	IF	Citations
73	The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. Cell Reports, 2018, 23, 2107-2118.	2.9	110
74	Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut, 2012, 61, 344-353.	6.1	108
75	A High-Throughput Functional Complementation Assay for Classification ofBRCA1Missense Variants. Cancer Discovery, 2013, 3, 1142-1155.	7.7	108
76	EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Research, 2008, 10, R109.	2.2	106
77	Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8409-8414.	3.3	106
78	BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. Journal of Clinical Investigation, 2016, 126, 2903-2918.	3.9	105
79	Targeting homologous recombination repair defects in cancer. Trends in Pharmacological Sciences, 2010, 31, 372-380.	4.0	100
80	Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nature Medicine, 2012, 18, 344-346.	15.2	99
81	BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Research, 2009, 11, R63.	2.2	98
82	What Makes Tumors Multidrug Resistant?. Cell Cycle, 2007, 6, 2782-2787.	1.3	97
83	XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data. BMC Bioinformatics, 2018, 19, 366.	1.2	94
84	Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. Annals of Oncology, 2015, 26, 2180-2192.	0.6	93
85	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Research, 2017, 77, e62-e66.	0.4	92
86	Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer. Cancer Research, 2009, 69, 6396-6404.	0.4	88
87	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Research, 2014, 16, R47.	2.2	86
88	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Science Translational Medicine, 2020, 12, .	5.8	86
89	A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node. Nanotechnology, 2010, 21, 355101.	1.3	85
90	Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. Nature Communications, 2017, 8, 15981.	5.8	83

#	Article	IF	Citations
91	Chromosome instability induced by Mps1 and p53 mutation generates aggressive lymphomas exhibiting aneuploidy-induced stress. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13427-13432.	3.3	82
92	Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours. Nature, 2012, 482, 538-541.	13.7	80
93	E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. Cancer Discovery, 2018, 8, 498-515.	7.7	79
94	Rapid target gene validation in complex cancer mouse models using reâ€derived embryonic stem cells. EMBO Molecular Medicine, 2014, 6, 212-225.	3.3	78
95	A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors. Clinical Cancer Research, 2010, 16, 99-108.	3.2	77
96	Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan. Cancer Research, 2010, 70, 1700-1710.	0.4	76
97	Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours. Nature Cell Biology, 2016, 18, 1346-1356.	4.6	75
98	The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity. Nature Communications, 2018, 9, 5406.	5.8	74
99	Oncogene addiction. Cancer Cell, 2004, 6, 535-538.	7.7	73
100	The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. Cancer Research, 2016, 76, 6084-6094.	0.4	73
101	Further Evidence for BRCA1 Communication with the Inactive X Chromosome. Cell, 2007, 128, 991-1002.	13.5	72
102	Fibroblast Growth Factor Receptor 1â€“Transformed Mammary Epithelial Cells Are Dependent on RSK Activity for Growth and Survival. Cancer Research, 2009, 69, 2244-2251.	0.4	72
103	Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression. Cell Reports, 2015, 10, 383-397.	2.9	70
104	Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Experimental Cell Research, 2007, 313, 133-145.	1.2	68
105	Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene, 2004, 23, 6047-6055.	2.6	65
106	Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. International Journal of Cancer, 2015, 136, 1434-1444.	2.3	64
107	Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma. Nature Genetics, 2017, 49, 1219-1230.	9.4	64
108	A Whole-Genome Mouse BAC Microarray With 1-Mb Resolution for Analysis of DNA Copy Number Changes by Array Comparative Genomic Hybridization. Genome Research, 2003, 14, 188-196.	2.4	62

#	Article	IF	Citations
109	Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. Nucleic Acids Research, 2008, 36, e13-e13.	6.5	62
110	Frat is dispensable for canonical Wnt signaling in mammals. Genes and Development, 2005, 19, 425-430.	2.7	61
111	Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. Cell Reports, 2018, 23, 100-111.	2.9	60
112	Mice Expressing a Mammary Glandâ€“Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development. Cancer Research, 2005, 65, 8166-8173.	0.4	59
113	Telomerase Deletion Limits Progression of p53-Mutant Hepatocellular Carcinoma With Short Telomeres in Chronic Liver Disease. Gastroenterology, 2007, 132, 1465-1475.	0.6	59
114	Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cellular and Molecular Life Sciences, 2012, 69, 223-245.	2.4	59
115	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. Nature Communications, 2019, 10, 397.	5.8	59
116	<scp>BRCA</scp> 1 and <scp>BRCA</scp> 2 tumor suppressors protect against endogenous acetaldehyde toxicity. EMBO Molecular Medicine, 2017, 9, 1398-1414.	3.3	57
117	Modeling Metastatic Breast Cancer in Mice. Journal of Mammary Gland Biology and Neoplasia, 2007, 12, 191-203.	1.0	55
118	A Preclinical Mouse Model of Invasive Lobular Breast Cancer Metastasis. Cancer Research, 2013, 73, 353-363.	0.4	54
119	Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8632-8637.	3.3	54
120	BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer, 2010, 10, 654.	1.1	53
121	Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors. Cancer Research, 2012, 72, 2350-2361.	0.4	48
122	Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling. Cancer Research, 2013, 73, 4937-4949.	0.4	47
123	BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance. Cancer Research, 2015, 75, 732-741.	0.4	47
124	Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors. Clinical Cancer Research, 2016, 22, 96-106.	3.2	47
125	Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer. Annual Review of Cancer Biology, 2019, 3, 235-254.	2.3	47
126	Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance. Current Pharmaceutical Design, 2009, 15, 1844-1853.	0.9	45

#	Article	IF	Citations
127	Polycomb group gene Ezh2 regulates mammary gland morphogenesis and maintains the luminal progenitor pool. Stem Cells, 2013, 31, 1910-1920.	1.4	42
128	PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma. Cell Reports, 2016, 16, 2087-2101.	2.9	42
129	Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors. Cancer Research, 2019, 79, 452-460.	0.4	42
130	Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression. Journal of Pathology, 2011, 224, 10-21.	2.1	41
131	Using the GEMM-ESC strategy to study gene function in mouse models. Nature Protocols, 2015, 10, 1755-1785.	5.5	41
132	Dominant-Negative but not Gain-of-Function Effects of a p53.R270H Mutation in Mouse Epithelium Tissue after DNA Damage. Cancer Research, 2007, 67, 4648-4656.	0.4	40
133	Novel Candidate Cancer Genes Identified by a Large-Scale Cross-Species Comparative Oncogenomics Approach. Cancer Research, 2010, 70, 883-895.	0.4	40
134	Analysis of Tumor Heterogeneity and Cancer Gene Networks Using Deep Sequencing of MMTV-Induced Mouse Mammary Tumors. PLoS ONE, 2013, 8, e62113.	1.1	40
135	In situ CRISPRâ€Cas9 base editing for the development of genetically engineered mouse models of breast cancer. EMBO Journal, 2020, 39, e102169.	3.5	40
136	Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. Molecular Cell, 2021, 81, 4692-4708.e9.	4.5	40
137	High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors. Genome Research, 2011, 21, 2181-2189.	2.4	39
138	In vivo analysis of Frat1 deficiency suggests compensatory activity of Frat3. Mechanisms of Development, 1999, 88, 183-194.	1.7	38
139	ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets. Nature Communications, 2013, 4, 2697.	5.8	37
140	Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2+ breast cancer. Pain, 2015, 156, 1424-1432.	2.0	37
141	Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models. BioEssays, 2011, 33, 701-710.	1.2	36
142	Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers. BMC Cancer, 2010, 10, 455.	1.1	35
143	Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547. Cancer Research, 2018, 78, 5668-5679.	0.4	35
144	TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development. Genes and Development, 2020, 34, 179-193.	2.7	35

#	Article	IF	Citations
145	Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. Nature Communications, 2021, 12, 4360.	5.8	35
146	Genetically engineered mouse models of PI3K signaling inÂbreast cancer. Molecular Oncology, 2013, 7, 146-164.	2.1	34
147	Î±Eâ€catenin is a candidate tumor suppressor for the development of Eâ€cadherinâ€expressing lobularâ€type breast cancer. Journal of Pathology, 2018, 245, 456-467.	2.1	34
148	BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny. Genes and Development, 2013, 27, 39-51.	2.7	33
149	EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy. Clinical Cancer Research, 2019, 25, 4351-4362.	3.2	33
150	Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression. Oncogene, 1999, 18, 5982-5990.	2.6	32
151	Mouse Models for Sporadic Cancer. Experimental Cell Research, 2001, 264, 100-110.	1.2	32
152	Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer. Oncotarget, 2017, 8, 54364-54377.	0.8	32
153	Insertional Mutagenesis in Mice Deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 Reveals Cancer Gene Interactions and Correlations with Tumor Phenotypes. Cancer Research, 2010, 70, 520-531.	0.4	31
154	Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoEâ€deficient mice. FASEB Journal, 2006, 20, 953-955.	0.2	29
155	Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resistance Updates, 2008, 11, 51-60.	6.5	29
156	Somatic loss of p53 leads to stem/progenitor cell amplification in both mammary epithelial compartments, basal and luminal. Stem Cells, 2013, 31, 1857-1867.	1.4	29
157	Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division. British Journal of Cancer, 2018, 118, 1586-1595.	2.9	29
158	Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining. Cell Reports, 2020, 32, 108068.	2.9	29
159	Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1796, 266-280.	3.3	28
160	Identification of Networks of Co-Occurring, Tumor-Related DNA Copy Number Changes Using a Genome-Wide Scoring Approach. PLoS Computational Biology, 2010, 6, e1000631.	1.5	27
161	The Use of Mass Spectrometry Imaging to Predict Treatment Response of Patient-Derived Xenograft Models of Triple-Negative Breast Cancer. Journal of Proteome Research, 2015, 14, 1069-1075.	1.8	27
162	<scp>BRCA</scp> 1 and Ct <scp>IP</scp> promote alternative nonâ€homologous endâ€joining at uncapped telomeres. EMBO Journal, 2015, 34, 410-424.	3.5	25

#	Article	IF	Citations
163	Characterization and Functional Analysis of the Murine Frat2 Gene. Journal of Biological Chemistry, 2004, 279, 26967-26974.	1.6	24
164	Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. Cell Cycle, 2010, 9, 3804-3815.	1.3	24
165	Somatic structural rearrangements in genetically engineered mouse mammary tumors. Genome Biology, 2010, 11, R100.	13.9	24
166	Computational identification of insertional mutagenesis targets for cancer gene discovery. Nucleic Acids Research, 2011, 39, e105-e105.	6.5	24
167	Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. Current Opinion in Genetics and Development, 2012, 22, 21-27.	1.5	24
168	EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors. PLoS ONE, 2012, 7, e45248.	1.1	24
169	Proteomics of Genetically Engineered Mouse Mammary Tumors Identifies Fatty Acid Metabolism Members as Potential Predictive Markers for Cisplatin Resistance. Molecular and Cellular Proteomics, 2013, 12, 1319-1334.	2.5	24
170	Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2Î². Laboratory Investigation, 2018, 98, 117-129.	1.7	24
171	Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin. Nature Communications, 2019, 10, 3800.	5.8	24
172	Mouse models for BRCA1 associated tumorigenesis: From fundamental insights to preclinical utility. Cell Cycle, 2008, 7, 2647-2653.	1.3	23
173	Proteomics of Mouse BRCA1-deficient Mammary Tumors Identifies DNA Repair Proteins with Potential Diagnostic and Prognostic Value in Human Breast Cancer. Molecular and Cellular Proteomics, 2012, 11, M111.013334-1-M111.013334-19.	2.5	23
174	Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and for growth inhibition of breast cancer cells and cancer stem-like cells.. Oncotarget, 2014, 5, 11827-11846.	0.8	23
175	Error-prone translesion replication of damaged DNA suppresses skin carcinogenesis by controlling inflammatory hyperplasia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21836-21841.	3.3	22
176	Mammary Tumorigenesis through LPA Receptor Signaling. Cancer Cell, 2009, 15, 457-459.	7.7	22
177	KC-SMARTR: An R package for detection of statistically significant aberrations in multi-experiment aCGH data. BMC Research Notes, 2010, 3, 298.	0.6	22
178	Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance. Scientific Reports, 2013, 3, 1949.	1.6	22
179	Development of metastatic HER2⁺ breast cancer is independent of the adaptive immune system. Journal of Pathology, 2011, 224, 56-66.	2.1	21
180	Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice. Clinical Cancer Research, 2017, 23, 7020-7033.	3.2	20

#	Article	IF	Citations
181	Use of a Single Hybrid Imaging Agent for Integration of Target Validation with In Vivo and Ex Vivo Imaging of Mouse Tumor Lesions Resembling Human DCIS. PLoS ONE, 2013, 8, e48324.	1.1	20
182	Aneuploidy Arises at Early Stages of Apc-Driven Intestinal Tumorigenesis and Pinpoints Conserved Chromosomal Loci of Allelic Imbalance between Mouse and Human. American Journal of Pathology, 2007, 170, 377-387.	1.9	19
183	Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2011, 16, 41-50.	1.0	19
184	Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays. Clinical Cancer Research, 2020, 26, 4559-4568.	3.2	19
185	A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture. Cancer Research, 2022, 82, 510-520.	0.4	18
186	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions. Cancers, 2021, 13, 5396.	1.7	17
187	The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice. Current Opinion in Genetics and Development, 2021, 66, 57-62.	1.5	16
188	Conditional Pten knockâ€out mice: a model for metastatic phaeochromocytoma. Journal of Pathology, 2009, 217, 597-604.	2.1	15
189	SMARCAD1-mediated active replication fork stability maintains genome integrity. Science Advances, 2021, 7, .	4.7	15
190	Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer. Oncotarget, 2016, 7, 63537-63548.	0.8	14
191	A tissue reconstitution model to study cancer cellâ€intrinsic and â€extrinsic factors in mammary tumourigenesis. Journal of Pathology, 2010, 220, 34-44.	2.1	13
192	MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression. Breast Cancer Research, 2012, 14, 324.	2.2	13
193	Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol. Cancer Prevention Research, 2012, 5, 1053-1060.	0.7	12
194	p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice. Journal of Mammary Gland Biology and Neoplasia, 2016, 21, 81-88.	1.0	12
195	Haploid genetic screens identify genetic vulnerabilities to microtubuleâ€targeting agents. Molecular Oncology, 2018, 12, 953-971.	2.1	12
196	Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system. OncoImmunology, 2020, 9, 1724049.	2.1	12
197	Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget, 2017, 8, 60750-60763.	0.8	11
198	Stuck at first base. Nature, 2002, 419, 127-128.	13.7	10

#	Article	IF	Citations
199	Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 141-150.	2.0	10
200	Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. Oncotarget, 2017, 8, 87638-87646.	0.8	10
201	Lack of Genomic Heterogeneity at High-Resolution aCGH between Primary Breast Cancers and Their Paired Lymph Node Metastases. PLoS ONE, 2014, 9, e103177.	1.1	9
202	Identifying transposon insertions and their effects from RNA-sequencing data. Nucleic Acids Research, 2017, 45, 7064-7077.	6.5	9
203	Feasibility of Phosphoproteomics on Leftover Samples After RNA Extraction With Guanidinium Thiocyanate. Molecular and Cellular Proteomics, 2021, 20, 100078.	2.5	9
204	Studying Drug Resistance Using Genetically Engineered Mouse Models for Breast Cancer. Methods in Molecular Biology, 2010, 596, 33-45.	0.4	9
205	Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFÎ² receptor I kinase. Journal of Pathology, 2015, 235, 745-759.	2.1	8
206	Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance. Oncogene, 2018, 37, 1594-1609.	2.6	8
207	Identification and Characterization of Collaborating Oncogenes in Compound Mutant Mice. , 1998, , 15-30.		8
208	Mouse models in the era of large human tumour sequencing studies. Open Biology, 2018, 8, .	1.5	7
209	BRCA1â€associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling. Journal of Pathology, 2018, 246, 41-53.	2.1	7
210	A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair. Cancer Research, 2021, 81, 6171-6182.	0.4	7
211	Potential value of color-coded dynamic breast-specific gamma-imaging; comparing 99mTc-(V)-DMSA, 99mTc-MIBI, and 99mTc-HDP in a mouse mammary tumor model. Applied Radiation and Isotopes, 2010, 68, 2117-2124.	0.7	6
212	Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms. Cancer Research, 2020, 80, 1486-1497.	0.4	6
213	PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair. Cancers, 2021, 13, 3604.	1.7	6
214	Epithelial-to-Mesenchymal Transition Drives Invasiveness of Breast Cancer Brain Metastases. Cancers, 2022, 14, 3115.	1.7	6
215	Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum. Cancers, 2021, 13, 1442.	1.7	5
216	Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer. Breast Cancer Research, 2022, 24, .	2.2	5

#	Article	IF	Citations
217	Filling in the gaps in PARP inhibitor-induced synthetic lethality. Molecular and Cellular Oncology, 2021, 8, 2010512.	0.3	4
218	GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice. Journal of Mammary Gland Biology and Neoplasia, 2019, 24, 271-284.	1.0	3
219	Abstract 2986: E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer. , 2018, , .		3
220	Treating the genetic make-up of breast cancer: a new fashion?. Expert Review of Anticancer Therapy, 2007, 7, 1065-1067.	1.1	2
221	Tracking Evolution of BRCA1-Associated Breast Cancer: Figure 1.. Cancer Discovery, 2012, 2, 486-488.	7.7	2
222	Prophylactic window therapy with the clinical poly(<scp>ADP</scp>â€ribose) polymerase inhibitor olaparib delays <scp>BRCA1</scp>â€deficient mammary tumour formation in mice. Journal of Pathology, 2017, 241, 511-521.	2.1	2
223	Exogenous ERÎ± Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice. Journal of Mammary Gland Biology and Neoplasia, 2019, 24, 305-321.	1.0	1
224	Studying cancer drug resistance using BRCA-deficient mouse mammary tumor organoids. Protocol Exchange, 0, , .	0.3	1
225	Abstract A8: The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials.. , 2013, , .		1
226	Abstract IA09: Replication fork stability confers chemoresistance in BRCA-deficient cells. , 2017, , .		1
227	Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids. STAR Protocols, 2022, 3, 101132.	0.5	1
228	Models for angiogenesis: From fundamental mechanisms to anticancer treatment research. Drug Discovery Today: Disease Models, 2007, 4, 75-82.	1.2	0
229	Editorial. Drug Resistance Updates, 2012, 15, 1.	6.5	0
230	Abstract 2140: Finding co-occurrence and mutual exclusiveness in DNA copy number data. , 2010, , .		0
231	Abstract 2208: High-resolution analysis of insertional mutagenesis screens to study genetic interactions in heterogeneous tumors. , 2010, , .		0
232	Abstract A14: Lack of tumor eradication of chemotherapy-sensitive BRCA1;p53-deficient mouse mammary tumors. , 2010, , .		0
233	Abstract 4563: Quantitative proteomics of genetic mouse models for human breast cancer: Identification of BRCA1-associated proteins involved in DNA-repair. , 2010, , .		0
234	Abstract 5109: Proteomics of murine BRCA1 deficient breast tumors identifies DNA repair proteins with prognostic value in human breast cancer. , 2011, , .		0

#	Article	IF	Citations
235	Abstract 4438: A membrane modulating strategy improves doxorubicin therapy in spontaneous mouse breast carcinoma. , 2011, , .		0
236	Abstract 2761: Co-administration of the short-chain sphingolipid N-octanoyl-glucosylceramide improves doxorubicin therapy by enhancing intracellular drug accumulation in vivo. , 2012, , .		0
237	Abstract LB-392: Loss of Rev7 causes PARP inhibitor resistance in BRCA1;p53-deficient mouse mammary tumor cells. , 2012, , .		0
238	Abstract SY08-01: Large-scale screens for cancer genes in the mouse. , 2012, , .		0
239	Abstract 3295: Systematicin vivoanalysis of PI3K pathway aberrations in a mouse model for invasive lobular carcinoma. , 2012, , .		0
240	Abstract PR3: Patient derived BRCA1-deficient triple-negative breast cancer xenografts develop resistance to DNA damaging agents via genetic and epigenetic mechanisms. Clinical Cancer Research, 2012, 18, PR3-PR3.	3.2	0
241	Abstract 3382: Formation of transient membrane channels targets doxorubicin resistance.. , 2013, , .		0
242	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. Journal of Cell Biology, 2013, 202, 2022OIA57.	2.3	0
243	Abstract IA08: Studying therapy response and resistance in mouse models of breast cancer. , 2013, , .		0
244	Abstract A059: Context-dependent regulation of breast cancer metastasis by E-cadherin and p120-catenin. , 2013, , .		0
245	Abstract A52: Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling. , 2013, , .		0
246	Abstract A083: Neutrophils promote metastasis of invasive lobular carcinoma. , 2013, , .		0
247	Abstract 2425: Exploiting DNA repair defects in breast cancer. , 2014, , .		0
248	Abstract 3141: Epithelial-to-mesenchymal transition and therapy resistance in BRCA1-associated breast cancer. , 2014, , .		0
249	Abstract IA9: Studying therapy response and resistance in mouse models of human breast cancer. , 2014, , .		0
250	PARP Inhibitor Resistanceâ€"What Is Beyond BRCA1 or BRCA2 Restoration?. Cancer Drug Discovery and Development, 2015, , 453-471.	0.2	0
251	Abstract IA07: Cancer-associated inflammation facilitates metastatic breast cancer and counteracts chemoresponsiveness. , 2015, , .		0
252	Abstract B77: The role of fibroblasts in invasive lobular breast carcinoma. , 2015, , .		0

#	Article	IF	Citations
253	Abstract 2394: Cancer-associated fibroblasts in invasive lobular breast carcinoma. , 2015, , .		0
254	Abstract IA04: Cancer-associated systemic inflammation facilitates breast cancer metastasis. , 2016, , .		0
255	Abstract 889: Dissecting the role of MYC in BRCA1-associated breast cancer. , 2016, , .		0
256	Abstract A45: Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways in triple-negative breast cancer. , 2016, , .		0
257	Abstract 2687: Rapid in vivo testing of tumor suppressors in ILC by CRISPR-Cas9 mediated somatic gene editing of the mammary gland. , 2016, , .		0
258	Abstract 673: The role of MYPT1/2, ASPP2 and MYH9 in invasive lobular carcinoma. , 2016, , .		0
259	Abstract IA07: Genetic determinants of tumor development, therapy response and resistance in mouse models of BRCA-deficient breast cancer. , 2017, , .		0
260	Abstract LB-329: MicroRNA profiling to identify novel determinants of platinum resistance in BRCA1/2-mutated high-grade serous ovarian cancer. , 2017, , .		0
261	Abstract 3453: Progression through mitosis promotes PARP inhibitor induced cytotoxicity in homologous recombination deficient cancer cells. , 2017, , .		0
262	Abstract 985: The EurOPDX EDIReX project: Towards a European research infrastructure on patient-derived cancer models. , 2018, , .		0
263	Abstract 1296: CanPathProâ€"development of a platform for predictive pathway modelling using genetically engineered mouse models. , 2018, , .		0
264	Abstract 5381: Understanding the genesis and oncogenic consequences of tandem duplicator phenotypes in human cancers. , 2018, , .		0
265	Abstract 1041: XenofilteR: Computational dissection of mouse and human reads in PDX and xenograft sequence data. , 2018, , .		0
266	Abstract 3259: When is cancer not really cancer: The PREvent Ductal Carcinoma In Situ Invasive Overtreatment Now (PRECISION)* initiative. , 2018, , .		0
267	Abstract 5115: Establishing tumoroid and mouse models for functional validation of progression markers in DCIS. , 2018, , .		0
268	Interplay of SMARCAD1 and BRCA1 at Replication Forks to Maintain Genome Integrity. SSRN Electronic Journal, 0, , .	0.4	0